Registration

Online:
https://www.ukr.de/veranstaltung/gvhgvl-2026

Sponsors

Abbvie Deutschland GmbH & CO. KG	2.000,00 €
Alexion Pharma Germany GmbH	2.000,00 €
Amgen GmbH	2.000,00 €
BeOne Medicines Germany GmbH	1.000,00 €
GlaxoSmithKline GmbH & Co. KG	3.000,00 €
Incyte Biosciences Germany GmbH	3.000,00 €
Johnson&Johnson	3.000,00 €
Medac GmbH	2.500,00 €
Miltenyi Biotec B.V. & Co. KG	2.000,00 €
MSD Sharp & Dohme GmbH	1.500,00 €
Neovii biotech*	10.000,00 €
Octapharma GmbH	2.000,00 €
Servier Deutschland GmbH	3.000,00 €
Takeda	2.000,00 €
Therakos (UK) Ltd	5.000,00 €

Sponsorship service for presentation and advertising purposes.

*We thank Neovii for the generous donation of the HJ Kolb award.

Philipp Beckhove
Regensburg

Andreas Beilhack
Würzburg

Friederieke Berberich-Siebelt
Würzburg

Heiko Bruns
Erlangen

Ronjon Chakraverty
Oxford

Nelson Chao
Durham

Matthias Edinger
Regensburg

Hermann Einsele
Würzburg

James Ferrara
New York

Markus Feuerer
Regensburg

Katharina Fleischhauer
Essen

Luca Gattinoni
Regensburg

Jana Gawron
Freiburg

Armin Gerbitz
Erlangen

Sakhila Ghimire
Regensburg

Marieke Griffioen
Leiden

Miriam Heemskerk
Leiden

Kai Hildner
Erlangen

Petra Hoffmann
Regensburg

Michael Hudecek
Würzburg

Lukas Jeker
Basel

Robert Jenq
Duarte

Leslie Kean
Boston

Hans Joachim Kolb
München

Mike Luu
Würzburg

Kristina Maas-Bauer
Freiburg

Nicola Maciocia
London

Andreas Mackensen
Erlangen

Markus Mapara
New York

Florent Malard
Paris

Carina Matos
Regensburg

Everett Meyer
Stanford

Tariq Misbah
Regensburg

Dimitrios Mougiakakos
Magdeburg

Fabian Müller
Erlangen

Sophie Paczesny
Charleston

Livius Penter
Berlin

Hannah Reimann
Erlangen

Johannes Schetelig
Dresden

Patrick Schlegel
Regensburg

Christoph Schmid
Augsburg

Kilian Schober
Erlangen

Alix Schwarz
München

M. Haroon Shaikh
Würzburg

Simone Thomas
Regensburg

Luca Vago
Mailand

Harald Wajant
Würzburg

Daniela Weber
Regensburg

Robert Zeiser
Freiburg

Alma Zernecke-Madsen
Würzburg

Venue

University Hospital Regensburg
Great Lecture Hall (A0)

Organisation

University Hospital Regensburg
Phone: +49 941 944-11627
Fax: +49 941 944-31647
kongresse@ukr.de

Condition for Participation & Cancelation

After your successful registration you will receive an invoice concerning your participation fee during the next days by email. Once registered your registration is binding. All payments must be made prior to the conference. Participation fees are due upon receipt of invoice without deduction. Please transfer the invoice amount before the event date. In case of a cancellation the cancellation statement must be in writing. The following processing fees apply: 8-3 working days before the event 50% of participation fee. In case of too late cancellation or absence without written cancellation the entire fee will be charged. A substitute participant may be submitted at any time.

Participation fees

Entire conference	100,00 EUR
Entire conference with evening event	150,00 EUR

G>H G>L
crc transregio 221

Comprehensive Cancer Center Ostbayern

BZKF Bayerisches Zentrum für Krebsforschung

CCC WERA

NCT NATIONALES CENTRUM FÜR TUMORERKRANKUNGEN WERA

Photo: Reinhard Andreesen
State: February 2026

SPITZE IN DER MEDIZIN.
MENSCHLICH IN DER BEGEGNUNG.

UKR Universitätsklinikum Regensburg

GRAFT VERSUS HOST
G>H
G>L
GRAFT VERSUS LEUKEMIA



Graft versus Host Competence Center
Department of Internal Medicine III

GvH/GvL 2026

17th International Symposium

University Hospital Regensburg, Great Lecture Hall (A0)
March 11 - 13, 2026

DIE DEUTSCHEN UNIVERSITÄTSKLINIKA®

ukr.de

Dear colleagues,

it is our great honour and pleasure to welcome you for the 17. GvH/GvL meeting, which will be hosted by the University Hospital Regensburg together with the DFG Collaborative Research Center TRR 221 on GvH & GvL.

Since the first GvH/GvL conference the idea of a focused and interactive meeting allowing extensive discussion among experts and young interested scientists seems to meet the needs and the interest of many colleagues involved in the field of allogeneic stem cell transplantation and clinical immunobiology, especially in times of exciting new developments like the clinical introduction of CAR-T cells.

Therefore, we are more than grateful that so many distinguished experts from all over the world have again accepted our invitation to contribute as speakers, chairs and discussants to a creative and stimulating 2026 meeting.

We hope you enjoy GvH/GvL 2026!

Your Local Scientific Committee

Matthias Edinger

Hermann Einsele

Wolfgang Herr

Petra Hoffmann

Ernst Holler

Hans-Jochem Kolb

Marina Kreutz

Andreas Mackensen

Hendrik Poeck

Daniela Weber

Daniel Wolff

Wednesday, March 11th, 2026

13.00 – 13.10

Welcome

Wolfgang Herr

13.10 – 14.45

Session I: GvL – Immunobiology: From DLI to specific cellular effectors

Chairs: Andreas Mackensen (Erlangen), Simone Thomas (Regensburg)

Speakers: Christoph Schmid (Augsburg): *Prophylactio, preemptive and therapeutic DLI*
Ronjon Chakraverty (Oxford, UK): *In vivo transfer of CD4+ T cells shapes CD8+ T cell differentiation trajectory in humans*
Michael Hudecek (Würzburg): *CAR-T therapy in the context of alloSCT*

ECR: Hannah Reimann (Erlangen): *Isolation and identification of CD4+ T cells targeting DM-sensitive antigens presented on mismatched HLA-DP alleles, as mediators of a selective GvL effect.*

14.45 – 15.30 Coffee Break

15.30 – 16.00

Keynote Lecture I: HLA and GvL

Speaker: Katharina Fleischhauer (Essen)

16.00 – 17.15

Session II: GvL - Targets

Chairs: Patrick Schlegel (Regensburg), Hans-Jochem Kolb (München)

Speakers: Nicola Maciocia (London, UK): *CAR-T cells for T - ALL*
Marieke Griffioen (Leiden, NL): *T-cell responses to minor histocompatibility antigens after HLA-matched alloSCT*
Kilian Schober (Erlangen): *Novel AML antigen identification approach*

17.15 – 18.00

Hans-Jochem Kolb Award Lecture

Chairs: Hans-Jochem Kolb (München), Philipp Beckhove (Regensburg)

Speakers: t.b.d.

Thursday, March 12th, 2026

8.30 – 10.15

Session III: GvL – Immune escape: HLA loss, oxidative stress, CTLA-4 and beyond

Chairs: Hermann Einsele (Würzburg), Fabian Müller (Erlangen)

Speakers: Miriam Heemskerk (Leiden, NL): *Advanced cellular therapies to prevent tumor escape*
Luca Vago (Milan, I): *HLA-Loss and relapse*
Dimitrios Mougiakakos (Magdeburg): *Oxidative Stress and relapse*
Livius Penter (Berlin): *CTLA-4 blockade in medullary and extramedullary AML*

10.15 – 10.45 Coffee Break

10.45 – 12.30

Session IV: New Platform Approaches

Chairs: Nelson Chao (Durham, USA), Harald Wajant (Würzburg)

Speakers: Hendrik Poeck (Regensburg): *Metabolites and Immunotherapy/GvL*
Luca Gattinoni (Regensburg): *Memory stem T cells in alloSCT*
Lukas Jeker (Basel): *Engineering HSCs for transplantation*

ECR: Mike Luu (Würzburg): *Intracellular mechanism of pentanoate in CAR-T cells*

ECR: Alix Schwarz (Munich): *Immunomodulatory metabolites define gut microbiome recovery at day +100 after alloSCT and associate with improved survival and reduced relapse risk*

12.30 – 13.45 Lunch Break

13.45 – 15.30

Session V: Current strategies for GvHD prophylaxis

Chairs: Armin Gerbitz (Erlangen), Robert Zeiser (Freiburg)

Speakers: Johannes Schetelig (Dresden): *ATG vs PTCy*
Everett Meyer (Stanford, USA): *Orca T prophylaxis*
Leslie Kean (Boston, USA): *Triumphs and Tradeoffs in GVHD Prophylaxis: Lessons from Abatacept and PT-Cy*
Matthias Edinger (Regensburg): *Treg treatment and prophylaxis*

15.30 – 16.00

Keynote Lecture II: Microbiome and mechanisms of immune modulation

Speaker: Robert Jenq (Duarte, USA)

16.00 – 16.45 Coffee Break

16.45 – 18.30

Session VI: Biomarkers of acute and chronic GvHD

Chairs: Ernst Holler (Regensburg), Alma Zernecke-Madsen (Würzburg)

Speakers: Jamie LM Ferrara: (New York, USA): *An update on MAGIC*
Sophie Paczesny (Charleston, USA): *Proteomics and machine learning for cGVHD biomarkers*
Daniel Wolff (Regensburg): *Biomarkers of chronic GvHD*

ECR: Sakhila Ghimire (Regensburg): *Calprotectin as a tissue biomarker in aGvHD*

ECR: Carina Matos (Regensburg): *1,25 Vitamin D3: A protective link in GvHD*

Social Evening

Friday, March 13th, 2026

8.30 – 10.30

Session VII: GvHD – Pathophysiology with focus on microbiota and immunomodulation

Chairs: Andreas Beilhack (Würzburg), Kai Hildner (Erlangen)

Speakers: Florent Malard (Paris, F): *FMT in GvHD*
Jana Gawron (Freiburg): *The Forgotten Site: Stomach GVHD in Allogeneic Stem Cell Transplantation*
Daniela Weber (Regensburg): *Antibiotics and Outcome*

ECR: Misbah Tariq (Regensburg): *Microbial metabolites and GvHD in mice and men*

10.30 – 11.00 Coffee Break

11.00 – 13.00

Session VIII: New players for treatment in acute and chronic GvHD

Chairs: Friederike Berberich-Siebelt (Würzburg), Petra Hoffmann (Regensburg)

Speakers: Kristina Maas-Bauer (Freiburg): *ROCK1/2 signaling*
Markus Y. Mapara (New York, USA): *IFNgR/STAT1 signaling*
Heiko Bruns (Erlangen): *The role of phagocytosis in immune regulation after alloSCT*
Markus Feuerer (Regensburg): *Tissue regulatory T cells*

ECR: M. Haroon Shaikh (Würzburg): *Lymph node stroma in regulation of acute GvHD*

13.00 Farewell